i-factor - search results
If you're not happy with the results, please do another search
i-FACTOR peptide enhanced bone graft is cost-effective compared to local autograft in ACDF surgery
Cerapedics has announced the publication of the results of a study to evaluate the cost-effectiveness of i-FACTOR peptide enhanced bone graft compared to autograft...
Cerapedics announces Canadian approval of i-FACTOR+ Matrix
Cerapedics has announced Health Canada approval of the company’s next-generation bone graft called i-FACTOR+ Matrix, making it the first market to approve the commercial...
i-FACTOR clinical results show higher fusion rate compared to allograft
Cerapedics has announced the publication of results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery in The...
ISASS bone grafting policy statement features i-FACTOR peptide enhanced bone graft
The International Society for the Advancement of Spine Surgery (ISASS) recently issued a new bone grafting policy that features i‑FACTOR peptide enhanced bone graft...
IVANOS study reveals i-FACTOR bone graft use more than doubles fusion rate when compared...
Level 1 evidence, presented at EUROSPINE 2018 in Barcelona, Spain, demonstrates that i-FACTOR peptide enhanced bone graft results in significantly higher rates of fusion...
Use of i-FACTOR peptide enhanced bone graft more than doubles fusion rate in uninstrumented...
The use of i-FACTOR peptide enhanced bone graft (Cerapedics) resulted in a 50% fusion rate, compared to a 20% fusion rate using allograft in...
i-FACTOR™: Small peptide, big impact
This article is sponsored by Cerapedics, Inc.
A FAST, RELIABLE AND PROVEN ALTERNATIVE TO AUTOGRAFT
i-FACTOR peptide-enhanced bone graft is challenging the gold standard in bone...
Two-year results show statistical superiority of Cerapedics’ I-Factor to autograft in cervical spine
Cerapedics has announced the publication of two-year follow-up data from a US Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial of...
Cerapedics awarded group purchasing agreement with Premier for I-Factor
Cerapedics has been awarded a group purchasing agreement with Premier, a healthcare improvement company.
The new agreement allows Premier members, at their discretion, to take...
FDA advisory committee panel not required for i-FACTOR premarket approval
An advisory committee panel meeting will not be required for the final review of the premarket approval application for i-FACTOR peptide enhanced bone graft.
Study supports use of i-FACTOR as alternative to autograft in chronic back pain surgery
i-FACTOR biologic bone graft features synthetic small peptide (P-15) technology that supports bone growth through cell attachment and osteoblast differentiation.
Cerapedics receives CE mark and TGA listing for i-FACTOR Flex FR biologic bone graft
P-15 bone graft technology now features enhanced handling with addition of purified silk fibres.
Cerapedics files PMA application with FDA for i-FACTOR peptide enhanced bone graft
The PMA application is supported by data from a pivotal clinical trial demonstrating that i-FACTOR bone graft can be used as an alternative to autograft harvesting in certain procedures.
Canada to be the first commercial market to launch Cerapedics new surgical implant
Cerapedics today announced that the Canadian Market would be the first to have the i-FACTOR+ MATRIX surgical implant fully commercially available. The implant will...
Cerapedics announces FDA approval of PMA supplement based on two-year clinical data
Cerapedics today announced that the US Food and Drug Administration (FDA) has approved the company's premarket approval (PMA) supplement for i-FACTOR peptide enhanced bone...
Cerapedics announces expansion of Colorado headquarters
Cerapedics has announced the expansion of the company's headquarters located in the Denver metropolitan area. Over the past 18 months, Cerapedics has grown from...
Cerapedics announces first patients enrolled in IDE clinical trial of P-15L bone graft for...
The first patients have been enrolled in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L peptide...
Cerapedics announces closing of US$22 million financing
Cerapedics has announced that the company completed a US$22 million financing led by KCK Group, a family investment fund that focuses on innovative medical...
Cerapedics receives FDA approval to initiate IDE study of P-15L bone graft for TLIF...
Cerapedics, a privately-held orthobiologics company, has announced the company received approval from the US Food and Drug Administration (FDA) to initiate an investigational device...
Peptide-enhanced bone graft outperforms autograft at two years
A prospective, multicentre trial has found that a peptide-enhanced bone graft is non-inferior compared to local autograft bone. In addition, the bone graft outperformed...
Novel biologic bone graft improves clinical outcomes in ALIF procedures
A new study published in the Journal of Neurosurgery: Spine indicates that Cerapedics' i-Factor biologic bone graft improves clinical outcomes patients undergoing ALIF.
